These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2410101)

  • 1. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
    Kennel SJ; Lankford PK; Flynn KM; Winegar R
    Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of a murine sarcoma using syngeneic monoclonal antibody.
    Kennel SJ; Lankford T; Flynn KM
    Cancer Res; 1983 Jun; 43(6):2843-8. PubMed ID: 6850596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts.
    Kennel SJ; Falcioni R; Wesley JW
    Cancer Res; 1991 Mar; 51(5):1529-36. PubMed ID: 1997194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
    Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
    Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.
    Ceriani RL; Blank EW
    Cancer Res; 1988 Aug; 48(16):4664-72. PubMed ID: 3396015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
    Powell TJ; Spann R; Nguyenduc M; Lamon EW
    J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Moloney murine lymphoma and sarcoma growth in vivo by dietary retinoids.
    Dillehay DL; Shealy YF; Lamon EW
    Cancer Res; 1989 Jan; 49(1):44-50. PubMed ID: 2783245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
    Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
    J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K; Bonavida B
    J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-induced inhibition of Moloney sarcoma virus-transformed cells: requirement for T-cells.
    Skicki-Mullen MB; Markovic SN; Murasko DM
    Cancer Res; 1989 Feb; 49(3):522-7. PubMed ID: 2463077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy.
    Katz JD; Lebow LT; Bonavida B
    J Immunol; 1989 Aug; 143(4):1387-95. PubMed ID: 2663994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
    Paciucci PA; Macphail S; Bach FH; Zarling JM
    J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
    Bateman WJ; Jenkinson EJ; Owen JJ
    Immunology; 1987 Jul; 61(3):317-20. PubMed ID: 2956180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
    Kaji R; Yoshida H; Yanagawa T; Sato M
    J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
    Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
    Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
    Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
    Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.